Results 1 to 10 of about 527 (153)

Cefepime-enmetazobactam: first approved cefepime-β- lactamase inhibitor combination for multi-drug resistant Enterobacterales. [PDF]

Future Microbiol
Cefepime-enmetazobactam is a β-lactam/β-lactamase inhibitor (BL/BLI) combination that has demonstrated potent activity against extended spectrum beta-lactamase (ESBL)-producing Enterobacterales, recently approved by the US FDA for the treatment of complicated urinary tract infections (cUTI) and by the European Medicines Agency and the UK Healthcare ...
Bhowmick T, Canton R, Pea F, Quevedo J, Santerre Henriksen A, Timsit JF, Kaye KS.   +6 more
europepmc   +9 more sources

Resistance of Gram-Negative Bacteria to Cefepime-Enmetazobactam: A Systematic Review [PDF]

Pathogens
Cefepime-enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination showing good activity against multidrug-resistant (MDR) Gram-negative bacteria producing a variety of β-lactamases.
Matthew E. Falagas, Laura T. Romanos, Dimitrios S. Kontogiannis, Katerina Tsiara, Stylianos A. Kakoullis   +4 more
doaj   +6 more sources

In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae [PDF]

Microbiology Spectrum
Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar
S. Albac, N. Anzala, P. Chavanet, N. Dunkel, J. Quevedo, A. Santerre Henriksen, D. Croisier   +6 more
doaj   +5 more sources

Evaluation of the activity of cefepime/enmetazobactam against Enterobacterales bacteria collected in Europe from 2019 to 2021, including third-generation cephalosporin-resistant isolates

Journal of Global Antimicrobial Resistance
: Objectives: This study was performed to investigate the activity of the novel ß-lactam/ß-lactamase inhibitor combination cefepime/enmetazobactam, against recently circulating Enterobacterales isolates from Europe from 2019 to 2021. Methods: A total of
Ian Morrissey, Stephen Hawser, Nimmi Kothari, Nathalie Dunkel, Juan Quevedo, Adam Belley, Anne Santerre Henriksen, Marie Attwood   +7 more
doaj   +6 more sources

Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016–2018 from USA and Europe: genotypic analysis of β-lactamases and comparative in vitro activity of cefepime/enmetazobactam

Journal of Global Antimicrobial Resistance, 2021
: Objectives: This study aimed to investigate third-generation cephalosporin (3GC) resistance determinants [extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases and OXA-type β-lactamases] in contemporary clinical Enterobacterales isolates and to ...
Adam Belley, Ian Morrissey, Stephen Hawser, Nimmi Kothari, Philipp Knechtle   +4 more
doaj   +4 more sources

CEFEPIME/ENMETAZOBACTAM: Physicochemical Stability of a Novel β-Lactam/β-Lactamase Inhibitor Combination in Syringes and Elastomeric Devices [PDF]

Antibiotics
Background: Cefepime/enmetazobactam (FEP/META) is a novel fixed-dose β-lactam/β-lactamase inhibitor combination. The objective was to study the physicochemical stability of the approved daily dose in polypropylene syringes and elastomeric devices over a ...
Akim Chayem, Juan Quevedo, Sandrine Cure, Noëlle Jemmely, Béatrice Demore, Beatriz Esteban-Cartelle, Brayan J. Anaya, Gabriel A. Peñalver, Dolores R. Serrano, Elise D’Huart   +9 more
doaj   +4 more sources

In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020

Journal of Microbiology, Immunology and Infection, 2022
Background/purpose: This study aimed to investigate the in vitro susceptibilities of carbapenem-non-susceptible Pseudomonas aeruginosa (CNSPA) and Acinetobacter baumannii (CNSAB) isolates to cefiderocol, novel β-lactamase inhibitor (BLI) combinations ...
Po-Yu Liu, Wen-Chien Ko, Wen-Sen Lee, Po-Liang Lu, Yen-Hsu Chen, Shu-Hsing Cheng, Min-Chi Lu, Chi-Ying Lin, Ting-Shu Wu, Muh-Yong Yen, Lih-Shinn Wang, Chang-Pan Liu, Pei-Lan Shao, Yu-Lin Lee, Zhi-Yuan Shi, Yao-Shen Chen, Fu-Der Wang, Shu-Hui Tseng, Chao-Nan Lin, Yu-Hui Chen, Wang-Huei Sheng, Chun-Ming Lee, Hung-Jen Tang, Po-Ren Hsueh   +23 more
doaj   +2 more sources

Cefepime and New Cefepime/Beta-Lactamase Inhibitor Combination for the Treatment of Gram-Negative Bacteria: Chemical Structure and Mechanism of Action, Microbiological Target, Clinical Use and PK/PD Characteristics [PDF]

Pharmaceuticals
The global spread of multidrug-resistant (MDR) Gram-negative bacteria, particularly extended-spectrum β-lactamase (ESBL)- and carbapenemase-producing Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, presents a significant public ...
Davide Carcione, Gioconda Brigante, Antonella Carducci, Jari Intra, Simone Ambretti, Floriana Campanile, Gabriele Arcari, Nicasio Mancini, Dario Cattaneo, Floriana Gona, Mariagrazia Perilli, Alessandra Piccirilli, Nicholas Geremia, Verena Zerbato, Stefano Di Bella, Giovanna Maria Nicolò, Luigi Principe   +16 more
doaj   +2 more sources

Cefepime Combined with Late-Generation β-Lactamase Inhibitors: Mechanisms of Action, In Vitro Activity, PK/PD Characteristics, Clinical Evidence and Resistance Mechanisms [PDF]

Antibiotics
Cefepime combined with late-generation β-lactamase inhibitors—enmetazobactam, zidebactam, and taniborbactam—represents a promising strategy to treat multidrug-resistant Gram-negative infections.
Sara Comini, Matteo Boattini, Paolo Gaibani, Gabriele Bianco   +3 more
doaj   +2 more sources

New β-Lactam/β-Lactamase Inhibitor Combination Antibiotics [PDF]

Pathogens
The growing problem of infections due to pathogens with antimicrobial resistance, especially Gram-negative bacteria, has led to the development of new β-lactam/β-lactamase inhibitor combination antibiotics.
Maria Sargianou, Panagiotis Stathopoulos, Christos Vrysis, Iva D. Tzvetanova, Matthew E. Falagas   +4 more
doaj   +2 more sources